Spruce Biosciences, Inc. (SPRB) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 96.30M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $96.30M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $54.08M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $48.91M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $10.67M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $16.39M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $25.61M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $38.75M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $60.05M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $69.68M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $81.15M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $96.34M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $98.80M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $97.48M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $73.93M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $24.49M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $21.65M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $47.21M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $23.34M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $42.75M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $58.36M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $78.28M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $148.63M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $157.15M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $72.16M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $36.60M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $41.41M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $3.92M | (m) | (m) |
| 2019-09-30 | (m) | (m) | $4.83M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |